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The synovial fluid proteome in juvenile idiopathic arthritis was investigated to isolate joint-specific
biomarkers that are expressed in patients displaying recurrent joint inflammation. To identify the
synovial specific proteome, matched synovial fluid and plasma samples were subjected to protein
separation by 2-dimension electrophoresis (2DE). Forty-three protein spots, overexpressed in the joint,
were identified. Synovial fluids from children with single-event knee joint inflammation were then
compared with a group with recurrent knee disease. Nine synovial specific proteins were significantly
differentially expressed in the recurrent group. Proteolytic fragments of collagen X, fibrin â-chain, and
T-cell receptor R-region have been identified among this protein cluster. Putative biomarkers,
overexpressed in the joint and differentially expressed in children with recurrent joint inflammation,
have been identified. These proteins may play a significant role determining the pathological state
within the chronically inflamed joint and influence disease progression in JIA. This is the first study of
the synovial proteome in children.
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Introduction
Juvenile idiopathic arthritis (JIA) comprises a group of
chronic, childhood onset, autoimmune diseases with variable
clinical presentations, outcomes, and therapeutic responses.
JIA is one of the commonest chronic diseases of childhood,
affecting one in every thousand children.
Previous studies over the past few decades have evaluated
outcome, in terms of clinical remission, physical disability and
radiographic damage.1,2 A high percentage of JIA patients may
develop unremitting inflammatory disease (40-60%), with a
considerably higher risk of developing progressive joint de-
struction (10%).3
JIA is divided into a number of clinically distinct subgroups
according to the ILAR criteria.4 These include oligoarthritis,
extended oligoarthritis, poly-articular rheumatoid factor-posi-
tive (RF +ve), polyarticular RF-ve, enthesitis, psoriatic, and
systemic disease. Joint inflammation is a feature common to
all. Ravelli’s review findings indicate that the long-term out-
come for JIA patients is best in persistent oligo-articular disease
and worst in the RF+ve poly-articular group. The widely
variable outcomes of JIA reflects the heterogeneity of inflam-
matory activity associated with a specific disease subtype.5,6
Although recent treatment strategies are more effective, reduc-
ing the frequency of severe disability, there remains a high
proportion of patients who continue to present with persistent
inflammatory disease into young adulthood.7 Moreover, it is
known that joint damage may progress despite decreased
inflammatory activity and erosions may develop in patients
with few signs of inflammation by conventional laboratory and
clinical assessments.5
Predicting the progression and consequence of JIA inflam-
matory pathology is therefore essential for optimal clinical
management. The current prognostic and therapeutic rationale
is focused on clinical evaluation and radiographic monitoring
of inflamed synovial joints and subsequent administration of
appropriate anti-rheumatic drugs.
We noted through clinical observation, that in some children,
recurrent joint inflammation occurred despite intra-articular
steroid treatment and irrespective of the disease subtype.
Although JIA was previously thought of as a benign disease, a
considerable number of JIA patients will continue to suffer
persistent inflammatory disease with a significant proportion
developing severe disabilities.8,9 We postulate that biomarkers
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may exist, which mediate persistence of inflammation across
the disease subtypes. A search for mediators of inflammation
persistence within a given joint might thus increase our
understanding of childhood inflammatory joint disease.
Others have looked for prognostic markers within disease
subgroups, for example some studies have attempted to identify
early prognostic factors, such as rheumatoid factor.8,10
More recently biomarker discovery studies on adult arthritis
have adopted a more rigorous and global analysis platform for
protein expression patterns based on two-dimensional elec-
trophoresis (2-DE) or liquid chromatography (LC) coupled with
highly sensitive mass spectrometry (MS).11,12 2-DE is a high-
resolution method for unscrambling complex protein mixtures
in two dimensions, according to their isoelectric point (pI) in
the first dimension and size (molecular weight) in the second
dimension. This large-scale characterization of the total protein
compliment, or proteome, was adopted in our investigation
to elucidate specific differences, in local pathology of the
inflamed joint. Rather than looking for differences between
disease subtypes we wished to look for protein markers which
would occur in those patients with recurrent joint inflammation
as opposed to those markers present in joints which responded
to treatment.
We therefore wished to look at two groups of patients; those
with a single episode of joint inflammation which settled
following intra-articular steroid and those with recurrence of
inflammation within that joint, despite treatment, during a
defined time period. We believe this might identify markers of
disease persistence common to all subtypes of JIA.
We believe it is essential to identify the synovial fluid
proteome from those proteins produced systemically and
secreted into plasma by a wide variety of non synovial cells, as
it is within the joint that destruction occurs.
Although the systemic component of JIA may be important,
this preliminary study has focused on elucidating those proteins
which are exclusively expressed or at least over represented
within the joint space.
We therefore wished to study the synovial proteome in JIA
and attempt to identify a specific proteome which occurred in
persistent disease.
Materials and Methods
Patients, Synovial and Plasma Samples. This paper de-
scribes three studies:
1. The Synovial Specific Proteome. In the first study, we
wished to identify the synovial fluid specific proteome. Six
patients (Table 1A) with matched plasma and synovial fluid
samples were used (2 with oligo-articular and 4 with poly-
articular arthritis). Having identified synovial fluid specific
proteins (vide infra) i.e., those only expressed in synovial fluid
we then used these data to compare the expression of these
proteins between solitary and recurrent episodes of joint
inflammation in our second study.
2. Synovial Expression Profile Associated with Inflamma-
tion Recurrence. Twenty-six patients with juvenile idiopathic
arthritis (JIA) according to ILAR criteria entered this second
study (Table 1B).4 There were 13 children with oligo-articular
arthritis and 13 with RF-ve poly-articular arthritis. Children
were monitored for a period of 3 y. During this period, all
subsequent swelling of a single identified joint was recorded,
with synovial fluid and plasma obtained at each treatment
intervention.
All patients were examined by a consultant rheumatologist,
(MR), who confirmed their diagnosis. For the purposes of this
second study, only initial synovial fluids were studied. Children
were divided into two groups, those with a solitary episode of
knee synovitis which resolved with a single steroid injection
and those with recurrent joint synovitis requiring multiple
steroid injections.
Intra-articular steroid (Triamcinolone acetonide) injections
of the knee were performed with ultrasound guidance, under
general anesthetic, with the dose determined by the size of the
joint. (Triamcinolone hexacetonide was not available during
the time of this study). Clinical details recorded included
Table 1. Clinical and Demographic Characteristics of the Study Subjectsa
1A
single event recurrent
no. 3 3
oligo/ poly 1/2 1/2
mean age (years) 9.3 ( 5.69 7.3 ( 4.04
male/female (n) 1/2 1/2
mean duration of JIA 6.0 ( 4.36 7.1 ( 6.47
1B
single event recurrent
inflammation group oligo poly* total oligo poly* total
no. 6 7 13 7 6 13
age (years) 9.8 ( 4.8 13.17 ( 5.78 11.5 ( 5.37 7.3 ( 3.83 7.83 ( 5.71 7.54 ( 4.46
male/female (n) 0/6 3/4 3/10 1/6 3/3 4/9
duration of JIA (years) 5.8 ( 3.19 8.17 ( 3.97 6.58 ( 3.8 1.71 ( 2.03 7.5 ( 3.83 2.58 ( 4.12
inflammation frequency (months) 10.3 ( 8.12 12.67 ( 7.47 11.5 ( 7.54
no. of swollen joints (n) 3.5 ( 0.71 2.5 ( 0.55 2.5 ( 0.88 3 ( 1.41 3.67 ( 1.63 3.1 ( 1.6
serum CRP (mg/l) 29.5 ( 34.3 36.1 ( 50.4 34.2 ( 43.6 8.7 ( 8.4 20.2 ( 27.1 15.6 ( 21.6
ESR (mm/hr) 45.5 ( 20.5 28.6 ( 28.9 33.4 ( 26.4 12.2 ( 9.9 15.7 ( 4.2 14.1 ( 7.2
NSAID (yes/no) 3/3 5/2 8/5 4/3 6/0 10/1
DMARD (yes/no) 1/5 2/5 3/10 0/6 3/3 3/9
a Values are the mean ( standard deviation or the number of subjects.  ) not determined; CRP ) C-reactive protein; ESR ) erythrocyte sedimentation rate;
* rheumatoid factor negative.
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subtype of JIA, age, sex, disease duration, local and general
disease activity and where appropriate -time to local recur-
rence, ESR and CRP. Local inflammation was defined as both
joint swelling and pain on physical examination.
3. Confirmation of Protein Identity and Change in Expres-
sion Over Time. In our third and final study, we followed the
expression of a specific group of biomarkers in the synovial
fluids of five individuals (2 with oligo-articular, 3 with poly-
articular arthritis) with recurrent joint inflammation at the time
of reaspiration. We hoped this would give us some insight into
the changes in protein expression during the time course of
the disease.
All synovial fluids (SF) were aspirated using an aseptic
technique and plasma obtained at the same procedure. The
SF and plasma samples were immediately centrifuged at 5000
 g for 15 min at 4 °C to remove any particulate or cellular
material, aliquoted and stored at -80 °C until analyzed. Medical
Ethics Committee approval was obtained for this study at Green
Park Healthcare Trust and patient assent and parent informed
consent given.
Sample Treatment. Proteins within patient fluids were
extracted and stabilized for 1 h at 4 °C by addition of M-PER
protein extraction reagent (Pierce Biotechnology Inc., Rockford,
USA) and a protease inhibitor cocktail (Roche Diagnostics
GmbH, Mannheim, Germany). Samples were subsequently
dialyzed overnight at 4 °C in distilled water to remove salts,
with 3.5 KDa cutoff membrane Slide-A-Lyzer cassettes (Pierce
Biotechnology Inc., Rockford, USA). Each purified patient fluid
was snap frozen in liquid nitrogen and lyophilized overnight
under vacuum on a Christ freeze-dryer (Martin Christ GmbH,
Osterode am Harz, Germany). Matched synovial fluid and
plasma samples were rehydrated in sample rehydration buffer
(8 M Urea, 2% CHAPS and 0.002% bromophenol blue) (Invit-
rogen Ltd., Paisley, UK), with gentle agitation to prevent
foaming. Protein concentrations were measured using the
PlusOne 2-D Quant kit according to manufacturer’s guidelines
(Amersham Biosciences UK Ltd., Bucks, UK).
2-Dimensional Gel Electrophoreisis (2-DE). 2-DE was per-
formed at room temperature with a ZOOM IPGRunner System,
an XCell SureLock Mini-Cell and associated power supply,
strips, gels, and reagents according to the manufacturer’s
guidelines (Invitrogen Ltd., Paisley, UK). A 200-íg portion of
soluble protein extract was made up to a total volume of 160
íL in sample rehydration buffer, containing final concentra-
tions of 20 mM dithiotreitol and 0.5% (v/v) pH 4-7 carrier
ampholytes (Invitrogen Ltd., Paisley, UK). Each sample was
applied to a linear pH 4-7 immobilized pH gradient (IPG) strip
and rehydrated overnight. Pilot runs with pH 3-10 carrier
ampholytes and IPG strips revealed most of the proteins
focused within the pH 4-7 range. The first dimension separa-
tion of proteins by isoelectric focusing (IEF) was performed in
triplicate (n ) 3) at 500 V for 4 h (1 mA/0.5 W limit per strip)
with a final 2000 V step for 45 min to obtain high quality
resolution. After IEF, the strips were equilibrated in NuPAGE
LDS Sample Buffer by two 15 min steps with gentle shaking,
first with 1.5% dithiotreitol (w/v) added as a reducing agent
and second with 125 mM iodoacetamide included to reduce
protein streaking by alkylation. Post-equilibration, IPG strips
were laid into single well 4-12% Bis-Tris gels and sealed in
with 0.5% agarose (w/v) in running buffer. 10 íL of SeeBlue
Plus2 protein molecular weight ladder was used per gel. The
second dimension (molecular weight) separation was achieved
with denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
run at 200 V for 50 min. Focused protein spots were fixed in-
gel with 40% methanol/ 7% acetic acid (v/v) in distilled water
for 15 min. Gels were washed thoroughly in distilled water and
stained overnight with GelCode Blue colloidal Coomassie stain
reagent (Pierce Biotechnology Inc., Rockford, USA).
Image Analysis. Gels were scanned as 16 bit gray scale Tif
image files with a GS-800 Calibrated Densitometer (Bio-Rad
Laboratories Inc., Hercules, USA) and the protein spot intensi-
ties were quantified using Phoretics 2D Expression software
package version 2005 build 1742.8 (Nonlinear Dynamics Ltd.,
Newcastle upon Tyne, UK). Spots were detected, matched and
volumes normalized within replicate (n ) 3) gel sets to create
‘master’ gels for a series of corresponding samples. In study 1
individual plasma and matched synovial fluid samples from
six patients were studied in triplicate. Using the analysis
software, triplicate gel images were combined to create six SF
and six plasma ‘master’ gels. Subsequent qualitative subtraction
of plasma from matched synovial fluid ‘master’ gels revealed
a population of proteins uniquely expressed in the joint in all
six patients.
In study 2, we recruited 26 patients; 13 with a single episode
of knee joint inflammation and 13 in whom inflammation in
that knee joint was recurrent. Only synovial fluid samples
obtained at the first episode of joint inflammation were studied.
Synovial fluids from the two groups were pooled. Master gels
were created, this time from five replicate gels for each group.
Quantitative differential spot analysis was performed on ‘mas-
ter’ gels from the two groups. The threshold for accepting a
meaningful variation was set at a 2-fold change and statistical
analysis to find significant differences between compared spots
was performed using the Student’s t-test (p < 0.05).
Protein Spot Extraction and Identification. Those proteins
from studies 1 and 2 that were expressed exclusively within
synovial fluid were identified by nanoelectrospray ionization
mass-spectrometry (nESI-MS). Protein spots were excised
manually using sterilized 200 íL pipet tips cut to suitable bore
width. Matched spots within replicate gels were pooled, washed
twice in distilled water and destained with 50 mM ammonium
bicarbonate pH 7.8 in 40% ethanol (v/v). The gel pieces were
finely chopped, dehydrated with acetonitrile and dried in HT-4
Series II centrifugal evaporator for 30 min (GeneVac Ltd.,
Ipswich, UK). Sequencing grade, modified trypsin (Promega
Corporation, Madison, USA) diluted (75 ng/íL) in 25 mM
ammonium bicarbonate was added to the gel pieces followed
by overnight digestion at 37 °C. Digested peptides were
extracted in 5% trifluoroacetic acid, 50% acetonitrile in ultra-
pure water with sonication for 6 min. After a gel pellet was
formed by brief centrifugation, the supernatant was desalted
using a C18 ZipTip (Pierce Biotechnology Inc., Rockford, USA)
and dehydrated in SC 210A Speed Vac vacuum evaporator
(Savant Instruments Inc., Hicksville, USA). Desalted peptide
digests were subjected to nanoelectrospray-ionization (nESI-
MS/MS) with a LCQ Deca ion trap-mass spectrometer (Ther-
moFinnegan, San Jose, USA), operated with dynamic exclusion
via LCQ Tune software. MS/MS data was collected by Xcalibur
and MS/MS ion search was performed by Mascot search engine
(Matrix Science Inc., Boston, USA), using the database NCBInr.
Mascot used the Mowse scoring algorithm.13 This indicates that
the identity is significant if it would be expected to occur at
random with a frequency of less than 5%.
2-DE Western Immunoblot. Western immunoblot was used
in order to confirm the mass spectrometry findings (of study
2) and further analyze protein expression over time (study 3).
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The focused protein spots from selected 2-DE gels were
transferred to 0.45 ím Biotrace NT nitrocellulose membrane
(Pall Corproration, Portsmouth, UK) with an XCell II Blot
Module, associated buffers and power supply, according to the
manufacturer’s guidelines (Invitrogen Ltd., Paisley, UK). Non-
specific binding was blocked overnight at 4 °C using 5% nonfat
milk in PBS with 0.1% Tween 20 (PBST) (Sigma-Aldrich
Company Ltd., Gillingham, UK). Anti-human monoclonal
primary antibodies to Collagen X (COL-10; Sigma-Aldrich Ltd.,
Gillingham, UK) and T-cell Râ receptor (T10B9; Biolegend, San
Diego, USA) were incubated with blotted membranes at a
dilution of 1:500 in PBST, for 1 h at RT. After the membranes
were washed 3 times (5 min each) with PBST, they were
incubated in horseradish peroxidase conjugated secondary
antibodies diluted to 1:2500-1:5000 in PBST (Sigma-Aldrich
Company Ltd., Gillingham, UK), for 1 h at room temperature.
After a further 6 washes, bands were visualized using Super-
signal West Pico chemiluminescent substrate (Pierce Biotech-
nology Inc., Rockford, U.S.A.), imaged with a Autochemi CCD
camera and analyzed with Labworks software version 4.0.0.8
(UVP Ltd., Cambridge, UK).
Results
1. The Synovial Specific Proteome. The simultaneous
analysis of individual paired plasma and synovial fluids from
six patients (Table 1A) was used initially to isolate joint-specific
protein expression profiles, without introducing bias from inter-
individual differences. Pilot 2-DE gels revealed that the majority
of proteins from the sampled fluids migrated to within the pH
4-7 range (results not shown). We determined intra- and inter-
sample variability in protein concentration by analyzing changes
in spot intensity over three replicate 2-DE gels, per sample.
Visual inspection of replicate sets indicated that spot intensity,
coordinate (pI/MWt) and intensities were similar between gels
run from the same sample, but significant differences were
noted between patient’s and more importantly between plasma
and synovial fluid.
Approximately 480 spots per gel in synovial fluid and 570
spots per gel in plasma were automatically detected by Phoretix
software analysis of scanned gel images. Protein spots were
uniquely numbered by synchronization to those in a reference
gel. Intensity differences in spots matched between synovial
and plasma master gels were also quantified.
A series of 43 synovial fluid proteins were isolated that
remained unmatched or were expressed at a higher level than
could be detected within the plasma. Statistical analysis of
intra-sample variance revealed 18 spots within this subgroup
were consistently expressed in all patients studied.
These putative synovial specific biomarker proteins are
identified in Figure 1A (spot nos. 44-480). Ten control spots
expressed with regular frequency across corresponding plasma
and synovial fluid samples are highlighted in Figure 1B and
were used for comparative purposes. Within this batch of
control protein spots, some proteins were found to be equally
represented between plasma and synovial fluid, while others
tended to predominate in plasma.
2. Synovial Expression Profile-Associated with Inflamma-
tion Recurrence. The demographic and clinical characteristics
of the patient cohort are summarized in Table 1B, with values
representing the mean ( standard deviation. The ‘single event’
group by definition had only one episode of knee joint
inflammation which settled following treatment. The recurrent
group had between two and four episodes of knee inflamma-
tion during the study period.
The recurrent group displayed a trend toward a lower mean
age of 7.54 ( 4.46 years at the initial inflammatory episode vs
11.5 ( 5.37 years for the patients with a single inflammatory
episode. The mean time period between bouts of joint inflam-
mation within the recurrent group is 11.5 ( 7.54 months.
In both groups the female-to-male ratio was 2:1. The
traditional markers of acute inflammation, C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR), were higher
in the single event group than in the recurrent. This finding
may reflect the novel categorization of the patients in this study
or indeed an outlier, as the standard deviation was wide.
Synovial fluid samples from patients with recurrent joint
inflammation (n ) 13) were compared by 2-DE to those with
nonrecurrent inflammation (n ) 13), shown in Figure 2.
Proteins that were differentially expressed between the two
groups were considered for selection as biomarker candidates.
Each group master gel was pseudo-colored as part of the
Phoretix comparative analysis, to isolate which proteins were
significantly over or under expressed in the recurrent patient
group. Green designated the single event inflammation group,
whereas purple was used for the recurrent group. This allows
a purely qualitative measure of the number, intensity and
location of proteins which predominate in either patient group.
Three particular areas (Figure 2A-C) within each master gel
were investigated in greater detail. Possible biomarker candi-
dates were selected if expressed at g2-fold intensity in recurrent
Figure 1. Isolation of synovial specific proteome. 2-DE reveals
480 spots per gel within the pH 4-7 range for synovial fluid
and 570 for plasma. A subpopulation of spots unique to (red
labels), or overexpressed (black) were detected in synovial fluid
(Figure 1A). Proteins present either exclusively in plasma (red),
or present both in plasma and synovial fluid (blue), (Figure 1B).
Intensity was determined by software analysis.
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inflammation samples compared to single event samples (or
vice versa). Since master gels were composed of triplicate runs
of pooled patient samples, each protein marker selection was
subjected to ANOVA statistical test (p < 0.05) to assess inter-
gel variation in spot intensity. The proteins with fold differences
in expression which reached statistical significance and their
identities, ascertained by nESI-MS/MS, are displayed in Table
2.
Nine of the 43 protein spots, specific to the synovial joint,
were overexpressed in the recurrent group. Six of these bio-
marker candidates, with sufficient yields from pepsin digests,
were identified by mass spectrometry with a high degree of
confidence (p < 0.05) in sequence homology relative to the
NCBInr database.
Spot nos. 266, 270, and 378 were identified as fibrin,
fibrinogen, and haptoglobin-1 respectively, though the differ-
ence in expression between patient groups was below the 2-fold
threshold for these proteins.
Spot nos. 292, 373, and 439 were identified as haptoglobin-
2, T-cell receptor type C and Collagen X with 3.10, 3.61, and
2.03-fold increased expression respectively in the recurrent
patient group.
3. Confirmation of Protein Identity and Change in Expres-
sion Over Time. T-cell receptor Râ and collagen X expression
profiles were selected for further investigation. The detection
of these proteins within the synovial fluid-specific cluster, from
patients with recurrent joint inflammation, identified them as
possible inflammatory biomarkers. The expression of T-cell
receptor Râ and collagen X was confirmed by immunoblot.
We subsequently investigated whether these two candidate
proteins were consistently expressed in synovial fluid samples
over time. Five individual patients with recurrent joint inflam-
mation were selected. We quantified the presence of these
proteins in their individual sequential SF samples over time.
The results for one individual are shown in Figure 3A. Here
Collagen X expression was limited to the initial inflammatory
episode, with a distinctive series of three 55 KDa spots, the
center spot being the most abundant. Collagen X expression
was detectable in 3 of the 5 individuals tested with recurrent
inflammation. The T-cell receptor Râ (TCR) fragment expres-
sion, on the other hand, was detected consistently in all
recurrently inflamed joints as demonstrated in the patient
shown in Figure 3A. Furthermore, in that patient, TCR frag-
ments were also present in the SF from the contralateral knee
(RK2) which subsequently became inflamed. The TCR frag-
ments appear as a series of faint spots with molecular weights
ranging from 15 to 50 KDa, with the most abundant being 15
KDa.
We used conventional single dimension electrophoresis
combined with Western blotting in order to establish whether
Figure 2. Synovial expression profiles correlated with chronic
inflammation. Master SF 2-DE gels (top) from two subgroups of
JIA patients (n ) 13 each) that display either single-event or
recurrent joint inflammation. Green pseudo-color designates the
single event sample group and purple represents the recurrent
inflammation group. Spots within areas A, B, and C indicated
by arrows were picked and analyzed by ESI-MS/MS. Synovial
specific spots are indicated by red labels.
Figure 3. Confirmation of proteomic biomarkers. Enlarged areas
from 2-DE-Western immunoblots for collagen X and T-cell
receptor peptides (Figure 3A) The immunoblots represent syn-
ovial fluid from a single individual displaying recurrent episodes
of inflammation of the left knee (LK), with subsequent inflam-
mation of the right knee (RK). Conventional 1D Western immu-
noblot for T-cell receptor peptides of individual’s synovial fluids
(one per lane) within the single and recurrent study groups
(Figure 3B).
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the 15 KDa TCR fragment was specific to the recurrent group.
The results are shown in Figure 3B. The expression of 24 KDa
and 47 KDa TCR fragments is confirmed within both the single
event and recurrent populations. However, band densitometry
reveals that these higher molecular weight forms predominate
in the single inflammatory event group. The recurrent patients
display a trend towards higher expression of the 15 KDa
fragment, confirming the initial 2-DE proteomic analysis.
Discussion
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous
group of chronic diseases with highly variable clinical presenta-
tions and outcomes. Laboratory testing for pathogenic or
prognostic biomarkers within joint fluid and peripheral blood
samples is limited. The advent of modern proteomic method-
ologies, namely 2-dimensional electrophoresis (2-DE) com-
bined with mass-spectrometry (MS), has provided the oppor-
tunity to characterize complex protein profiles within synovial
fluid or plasma.
The dynamic milieu of synovial fluid is of particular interest
as it is composed not only of ultra-filtrated proteins (or cleaved
peptides) originating in serum, but also proteins exclusively
expressed and secreted by cells localized within the synovial
membrane, fluid or cartilage.
The synovial proteome of JIA is likely to be distinct from that
found in adult RA. This is because the genetics of JIA are quite
different from that of adult disease, the immunology is differ-
ent, and joint erosion much less common. Furthermore, since
children are growing, this may profoundly influence the balance
between inflammation and repair mechanisms within the joint.
The ideal biomarker of persistent inflammation in JIA should
fulfill a number of criteria, including: detectable levels in early
disease, expression which coincides with each inflammatory
episode and expression that is restricted to the inflamed joint.
We have applied these selection criteria in the current study
and have identified a number of putative candidates.
Fibrin(ogen) and haptoglobin precursors, mature active
molecules and peptide chain fragments have been positively
identified in the current study. Only fibrinogen beta (spot no.
270) and haptoglobin-2 beta (spot no. 292) chains were
exclusive to the synovial fluid and overexpressed within the
recurrent inflammation patient group. However, since these
proteins are not restricted to synovial fluid, have decreased
expression levels within recurrent patients, dismisses them as
putative biomarkers.
Several proteins have been identified in adult rheumatoid
arthritis (RA) and osteoarthritis (OA) patients by conventional
2-DE/MS methodologies, though JIA had to date remained
unstudied. Synovial joint-specific biomarkers identified in
adults include calgranulins A, B, and C,12,14 fibrinogen â-chain
and fructose bisphosphonate aldolase A and alpha-enolase.15
Serum amyloid A (SAA) has been found at increased levels in
both plasma and synovial fluid in adult RA patients. A broad
range of markers, including C-reactive protein16 and haptoglo-
bin,11,14 consistent with a chronic inflammatory condition have
also been observed.
Additional proteomic studies on progressive joint disease in
adults have concentrated on other aspects of the molecular
pathology including the presence of autoimmune antigens,17
or monitoring of patient response to anti-TNFR therapy.18 The
authors of a recent, highly relevant study of systemic-onset JIA
patients, were able to distinguish responses to an experimental
anti-IL-6 receptor therapy. However this study was based on
analysis of serum, and of the 23 proteins noted only SAA was
discussed.19
We have identified the presence of collagen X and T-cell
receptor Râ (TCR) fragments at significantly higher levels within
synovial fluids of patients suffering recurrent episodes of
inflammation. These may be putative biomarkers of disease
persistence.
Collagen X expression was just over 2-fold higher than in
the single inflammatory event group. It was found to be limited
to the initial inflammatory episode with levels falling in later
samples analyzed. Collagen type X is an extracellular matrix
component normally restricted to the interface of articular
cartilage and bone.20 It is exclusively synthesized by chondro-
cytes in the growth plate cartilage, though there are conflicting
views as to whether a thin ‘seam’ of permanent collagen X
Table 2. Identification and Quantification of Inflammation-Associated Proteinsa
spot
ID protein ID
mowse
score
no. of peptide
queries matched accession pI
mass
(KDa)
unique to
synovial fluid
fold difference in
recurrent patients
spot in
figure
M myoglobin marker control 17 n/a n/a 1B,2
33 not identified 6.73 114 X 6.25 1A
94 serum albumin precursor 121 5 AAF01333 5.77 75 -1.97 1B
163 serum albumin chain A 121 5 CAA23754 6.36 63.5 -1.48 1B
181 serum Abumin 308 14 AAF01333 6.08 63 -0.39 1B
241 not identified 5.64 51.5 -3.21 2A
245 not identified 5.76 50.2 -4.63 2A
266 fibrin beta chain 77 2 0401173A 5.69 47.5 X -1.1 1A,2A
270 fibrinogen beta chain 92 3 AAA52687 6.21 47.1 X 1.96 1A,2A
285 haptoglobin precursor 129 6 NP 5.08 46 -2.48 1B,2B
292 haptoglobin-2 beta chain 119 6 005 134 6.03 46.6 X 3.1 1A,2A
308 not identified 5.37 42 X 1.44 1A,2B
354 serum albumin 119 3 AAA64922 5.79 22.1 2.36 2C
356 not identified 5.74 24.2 X -2.17 1A,2C
364 haptoglobin-2 alpha 94 5 701184A 5.92 18.5 -1.78 1B,2C
373 T-cell receptor type C alpha region 79 1 AAB86742 5.03 15.3 X 3.61 1A,2
378 haptoglobin-1 alpha chain 100 5 681073A 5.19 16.6 X -1.84 1A,2C
401 ATP-citrate (pro-S-)-lyase 86 1 CAA45614 4.78 5 -1.59 1B
417 proapolipoprotein 250 11 AAA51747 5.45 26 -3.23 1B,2C
439 collagen X (subunit 3) 81 3 CAA42933 6.05 55.5 X 2.03 1A,2A
465 Ig kappa chain C region 78 1 A37927 6.45 26 -2.54 1B
a Spot trypsin digests were identified using nano-electrospray mass spectra (nESI-MS/MS), correlated to compiled peptide data (matrixscience). A positive
control spot picked from the 2-DE gel molecular weight markers was correctly identified as myoglobin.
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remains in the mature adult.21 In the context of recurrent
inflammation it is intriguing to find a product of hypertrophic
cartilage as a possible biomarker.
Other studies on collagen X postulate that it’s deposition
correlates with the initiation of calcification in bone forma-
tion,22 whereas others suggest that collagen X can produce focal
inhibition of calcification.23 The fragments identified themselves
could also play a pathological role in the initiation or develop-
ment of joint inflammation. The effects of specific type XVIII
collagen fragments, for example endostatin,24 on the process
of angiogenesis are well documented in a number of disease
states including arthritis.25 Furthermore, increases in collagen
I fragments correlate with disease activity scores in adult RA,26
whereas collagen II is associated with joint inflammation in
juvenile arthritis due to an autoimmune reaction.27
However, in our study since the expression of collagen X is
relatively low and is restricted to the initial episodes of
inflammation, it may be more indicative of growth, repair, or
degenerative change at the bone-cartilage interface.
Further work is required to validate collagen X as a conclu-
sive biomarker.
Distinct TCR fragment patterns were consistently detected
in the synovial fluid of persistently inflamed joints and within
other joints in the same patient. This might suggest that
inflammation in JIA is mediated by specific T cell clones.
The detection of TCR protein is not unique to JIA but may
be detected in a wide range of inflammatory conditions. What
may be specific to JIA though, is the oligoclonality of the TCR.
Previous studies have provided evidence of the clonal
expansion of specific T-cells which accumulate preferentially
in the synovial compartment.28,29 The identification of expanded
oligoclonal TCRs within and between individual JIA patients
has also been previously observed.30 The common TCR frag-
ments identified in this study, suggest local (synovial) stimula-
tion by a limited number of antigens. Furthermore, the
observation of two identical TCR expression patterns in two
distant joints, of an individual, may indicate that cells which
enter and proliferate within the inflamed joint are a select
subgroup from the peripheral T cell population.
In a separate study of TCR oligoclonality in a single JIA
patient, a converse relationship has also been identified. Here,
T cell clones were actively excluded from the inflamed joint.23,31
Our results are in agreement with earlier TCR studies, though
we provide data which suggests that the T cell contribution to
inflammation extends beyond early stage disease and could be
a requirement for the perpetuation of inflammation. The
western blot band densitometry of individual synovial fluids
revealed that the lower molecular weight (15 KDa) TCR
fragments predominate in the recurrent patient group. Ques-
tions remain as to whether the demonstrated TCR fragments
are functionally active or whether they are a product of
constitutive degradation or recycling.
This is the first study to characterize the synovial proteome
from patients with JIA. It has revealed a small subset of
biomarkers which may play a specific role in determining the
pathophysiological state within the chronically inflamed joint.
It is unfortunate that a number of spots with the most
dramatic changes (33, 241, 245, and 356) had unsufficient
protein yields within gel digests to be definitively identified.
The protein loading and sensitivity of the 2-DE technique will
be improved in future studies by progressing to larger format,
higher capacity gels with fluorescent Cy dye labeling of samples.
Further studies will be necessary to evaluate the clinical
significance of these putative biomarkers.
It could be argued that a study comparing the subgroups of
JIA, i.e., Oligo vs Poly might have been more appropriate. Our
hypothesis was that, irrespective of JIA subtype, markers of
disease persistence may exist that are common to all sub-
groups. This pilot study was looking for change that could be
measured over time. Thus, the recurrence of joint inflammation
was a useful event that could be tracked over time and
correlated to findings at outset.
Having demonstrated that it is possible to identify the JIA
proteome, we wish to validate our findings in a further cohort
of patients with newly diagnosed JIA in order to compare the
synovial proteome with in JIA subsets and to verify whether
the markers we have identified do truly predict disease
progression.
Abbreviations. JIA, juvenile idiopathic arthritis; TCR, T cell
receptor; RA, rheumatoid arthritis; SF, synovial fluid; OA,
osteoarthritis; RK, right knee; ESI-MS, electrospray ionization-
mass spectrometry; MWt, molecular weight; ESR, erytrocyte
sedimentation rate; CRP, C-reactive protein; RF, Rheumatoid
Factor.
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